rTMS in Wilson Disease Dysarthria (WILSTIM2)
Wilson Disease
About this trial
This is an interventional treatment trial for Wilson Disease focused on measuring dyasarthria, repetitive transcranial magnetic stimulation
Eligibility Criteria
Inclusion Criteria:
- Conseting adult patients with social insurance
- Wilson disease with dystonic hyperkinetic dysarthria
- Stable pharmacological therapy n the last 6 monts
- Brain MRI in the previous 6 months, without additional brain lesion
- Patients that did not receive botulinium toxin in the previous 4 months
Exclusion Criteria:
- Incapacitated adult
- Previous mdedical history of epilepsia
- Pregnancy or breastfeeding
- Brain lesion outside basal ganglia on brain MRI
- Patient consider by the investigator not able to sustain an 30 minutes rTMS session without moving
- Vocal chord lesion
- Previous history of laryngeal surgery
- rTMS contra indication
Sites / Locations
- Service de Physiologie Clinique-Explorations Fonctionnelles, AP-HP, Hôpital Lariboisière
- Service de Neurologie, Hopital Fondation Adolphe de RothschildRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Experimental stimulation
Sham stimulation
Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
Patients receive a treatment of rTMS using placebo coil (MCF P B65 coil) for 30 minutes at 1Hz (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).